Aptus Pharma Ltd (APPL) is currently trading at 491.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Aptus Pharma Limited is a BSE‑SME listed India‑based pharmaceutical marketer and distributor that operates an asset‑light model, promoting over 300 branded formulations across acute, chronic and OTC/wellness segments while using WHO‑GMP contract manufacturers and loan‑license facilities to supply markets. The company reported a strong H1 FY27 with revenue of ₹48.92 crore, EBITDA ₹7.68 crore and PAT ₹5.07 crore, delivering nearly 2x year‑on‑year revenue growth and signalling meaningful operational leverage for a small‑cap regional player transitioning to national scale. Aptus is pursuing a material strategic pivot: target 20% own manufacturing by March 2028 and a pan‑India presence by March 2029, which represents a shift from pure contract manufacturing toward partial vertical integration and broader geographic expansion. The balance sheet shows rapid change: share capital rose after a bonus, reserves and borrowings increased, inventories expanded materially and management has approved a high‑value preferential issue of ~₹44.88 crore (pending approvals), indicating active capital restructuring to fund growth. The business mix is heavily weighted to acute therapies (~44%), with chronic, wellness/OTC and services making up the balance, suggesting the company plans to deepen chronic and consumer healthcare verticals while leveraging its 10,000+ doctor network and 250+ distributor relationships for scale.

Over the past 52 weeks, Aptus Pharma Ltd has traded between a low of ₹48.10 and a high of ₹510.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Aptus Pharma Ltd has a market capitalization of approximately 842.92. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Aptus Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 106.03 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 842.92 Cr, Aptus Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Aptus Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Aptus Pharma Ltd is 106.03. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The board approved a preferential allotment of 16,02,870 equity shares at ₹280 per share, raising ₹44.88 crore, and also approved convening the 16th AGM on September 14, 2026.

They approved a 3:2 bonus share issue and an increase in authorised share capital from ₹7.15 crore to ₹25.00 crore, with 100% votes in favour.